Logo
x

Search

Subscribe Now

Diagnosed

Lilly's Bamlanivimab (LY-CoV555) Receives the US FDA's EUA for the Treatment of Recently Diagnosed COVID-19

Lilly's Bamlanivimab (LY-CoV555) Receives the US FDA's EUA for the Treatment of Recently Diagnosed COVID-19

  • November 10, 2020
Roche Reports Results of Tecentriq in P-III IMagyn050 Study for Women with 1L Newly Diagnosed Advanced Stage Ovarian Cancer

Roche Reports Results of Tecentriq in P-III IMagyn050 Study for Women with 1L Newly Diagnosed Advanced Stage Ovarian Cancer

  • July 13, 2020
Genmab

    Genmab's Darzalex Faspro (daratumumab and hyaluronidase-fihj) Receives the US FDA's Approval for Patients with Newly Diagnosed Lig...

    • January 18, 2021
    Lilly

      Lilly's Bamlanivimab (LY-CoV555) Receives the US FDA's EUA for the Treatment of Recently Diagnosed COVID-19

      • November 10, 2020
      Takeda Reports Results of Ninlaro (ixazomib) in a P-III Clinical Study for Newly Diagnosed Multiple Myeloma

        Takeda Reports Results of Ninlaro (ixazomib) in a P-III Clinical Study for Newly Diagnosed Multiple Myeloma

        • September 10, 2020
        Roche Reports Results of Tecentriq in P-III IMagyn050 Study for Women with 1L Newly Diagnosed Advanced Stage Ovarian Cancer

          Roche Reports Results of Tecentriq in P-III IMagyn050 Study for Women with 1L Newly Diagnosed Advanced Stage Ovarian Cancer

          • July 13, 2020
          Novocure and ZaiLab

            Novocure and ZaiLab's Optune Receive NMPA's Approval for the Treatment of Newly Diagnosed and Recurrent Glioblastoma

            • May 14, 2020
            BMS Reports Results of Triple Regimen in P-III ELOQUENT-1 Study for Patients with Newly Diagnosed Untreated Multiple Myeloma

              BMS Reports Results of Triple Regimen in P-III ELOQUENT-1 Study for Patients with Newly Diagnosed Untreated Multiple Myeloma

              • March 9, 2020
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.